A critical juncture for synthetic biology

Publication date: 12/06/2018

The development of new technologies and their applications often have to navigate regulatory limitations and public attitudes, expectations or resistance – the trajectories of genetically modified crops in the Europe or the success of in vitro fertilization after initial resistance demonstrate how public attitudes and regulation can determine if a technology succeeds or fails.

Academic scientists and companies working on new technologies increasingly must consider these factors and mitigate real and perceived risks of the technology so as to avoid overreaching regulation and public resistance that could threaten innovation. In this context, social science takes an important role by gauging public attitudes about if and how the emergence of new technologies stokes fears and raises hopes.

This article illustrates how the natural sciences and social sciences interacted in the emerging fields of synthetic biology and nanotechnology, specifically the timing and rise of social science research and commentary on the potential impact and risks of these emerging technologies.

Resource type: Web page URL

Risk in synthetic biology – views from the lab

Publication date: 01/06/2018

The concepts of risk and responsibility are often linked to discussions of emerging scientific fields, but studies into how these concepts are connected to research practices have been narrowly focused on risks for humans and the environment.

To broaden these concepts, “Responsible Research and Innovation” (RRI), a democratic governance framework, aims to enable societal discussions beyond traditional risk assessment and mitigation. Proponents of RRI argue that these discussions should not be confined to the direct risks of the research itself, but also include wider issues, such as “the purposes and motivations of research” [1]. Yet, it is not only RRI protagonists who want to broaden this conversation.

We found that scientists also ponder non‐technical risks, such as the impact of institutional demands on career, health and social relationships, or economic pressures from the incentive system in which much of research in biology is now embedded. These findings challenge the present formulation of RRI as a science governance framework and lead us to argue that “responsible” research and innovation systems can only succeed if these broader concerns are taken as seriously as the risk of laboratory accident or inadvertent release.

Resource type: Adobe Acrobat (.pdf)

Who’s talking about non-human Genome Editing? Mapping public discussion in the UK

Publication date: 31/05/2018

This report reviews public discussion about Genome Editing in non-human organisms. Its primary goal is to provide a preliminary baseline regarding the kinds of public discussion about, and interactions with, a development in biotechnology with societal significance.

Previous research and experience governing emerging technologies has shown that they need to be developed in ways that are ethical, safe and accountable, that deliver meaningful public value and that foster public trust in democratic institutions. Past experience in Britain suggests public deliberation and discourse has a vital role to play in developing effective governance arrangements and the nation has developed significant institutional expertise in developing such arrangements.

To date, attention has focused largely on the use of Genome Editing in humans. For instance, in 2015 an international summit produced a consensus statement on human Genome Editing. This was followed by a consensus study by the US National Academies of Sciences, Engineering, and Medicine into the ethics and governance of human Genome Editing, published in 2017. However, Genome Editing techniques span virtually all domains of bioscience and biotechnology that rely on altering genetic sequences. In today’s landscape, this means their envisaged uses in both scientific research, as tools, and in developing new technologies or commercially-valuable processes are widespread. It is therefore vital that non-human applications are considered.

In the UK, the Nuffield Council on Bioethics recently concluded an initial study on the ethics of Genome Editing and is undertaking follow up studies on human Genome Editing and Genome Editing in livestock. The Wellcome Trust is currently funding public engagement on Genome Editing as applied to human health and medicine through the Genome Editing Public Engagement Synergy with the National Coordinating Centre for Public Engagement. This review complements the above work by providing baseline information about public discussion of, and public engagement with, Genome Editing in non-human contexts.

Resource type: Adobe Acrobat (.pdf)

Soil pollution – a hidden reality

Publication date: 02/05/2018

Soil pollution poses a worrisome threat to agricultural productivity, food safety, and human health, but far too little is known about the scale and severity of that threat,

Concerns about soil pollution are growing in every region. Recently, the United Nations Environmental Assembly (UNEA-3) adopted a resolution calling for accelerated actions and collaboration to address and manage soil pollution. This consensus, achieved by more than 170 countries, is a clear sign of the global relevance of soil pollution and of the willingness of these countries to develop concrete solutions to address the causes and impacts of this major threat.

The main anthropogenic sources of soil pollution are the chemicals used in or produced as byproducts of industrial activities, domestic, livestock and municipal wastes (including wastewater), agrochemicals, and petroleum-derived products. These chemicals are released to the environment accidentally, for example from oil spills or leaching from landfills, or intentionally, as is the case with the use of fertilizers and pesticides, irrigation with untreated wastewater, or land application of sewage sludge. Soil pollution also results from atmospheric deposition from smelting, transportation, spray drift from pesticide applications and incomplete combustion of many substances as well as radionuclide deposition from atmospheric weapons testing and nuclear accidents. New concerns are being raised about emerging pollutants such as pharmaceuticals, endocrine disruptors, hormones and toxins, among others, and biological pollutants, such as micropollutants in soils, which include bacteria and viruses.

This book aims to summarise the state of the art of soil pollution, and to identify the main pollutants and their sources affecting human health and the environment, paying special attention to those pollutants that are present in agricultural systems and that reach humans through the food chain. It concludes with some case studies of the best available techniques for assessing and remediating contaminated soils.

 

Resource type: Adobe Acrobat (.pdf)

A global observatory for gene editing

Publication date: 21/03/2018

In August 2017, scientists reported that they had used the gene-editing tool CRISPR–Cas9 to correct a mutation in viable human embryos. The work is just one of countless applications of the technique, with which scientists hope to alter plants, animals and humans.

The value of most applications of the technology has barely been exposed to public review. Unless these editorial aspirations are more inclusively debated, well-intentioned research could move humanity closer to a future it has not assented to and might not want.

Over the past three years, leading scientists have called for global deliberation on the possible effects of gene editing on the human future. In our view, the discussions that have taken place fall far short of the expansive, cosmopolitan conversation that is needed.

Free enquiry, the lifeblood of science, does not mean untrammelled freedom to do anything. Society’s unwritten contract with science guarantees scientific autonomy in exchange for a research enterprise that is in the service of, and calibrated to, society’s diverse conceptions of the good. As the dark histories of eugenics and abusive research on human subjects remind us, it is at our peril that we leave the human future to be adjudicated in biotechnology’s own “ecclesiastical courts”.

It is time to invite in voices and concerns that are currently inaudible to those in centres of biological innovation, and to draw on the full richness of humanity’s moral imagination. An international, interdisciplinary observatory would be an important step in this direction.

Resource type: article: Web Page

Rethink public engagement for gene editing

Publication date: 12/03/2018

Over the past three years, thousands of articles have been published about editing genes and genomes. Apart from a public dialogue run by the Royal Society at the end of last year, there’s been little attempt to engage the public on the implications of the technology in a way that could alter the decisions of scientists and policymakers. Indeed, concern about the lack of effective public engagement has motivated several workshops, including one by the intergovernmental Organisation for Economic Co-operation and Development (OECD).

If the history of public engagement surrounding other recent scientific innovations is a guide, efforts to explain the science behind gene editing will intensify, such as through news stories, at science festivals, in public lectures and in museums. And there will be a rash of small, disconnected workshops involving members of the public that are designed to inform specific policy decisions.

If this is all that happens, scientists and policymakers will be ill prepared for the public debate that will almost certainly erupt as applications proliferate.

  • Linked page includes option for .pdf download.
Resource type: article: Web Page

The gene-editing conversation

Publication date: 31/01/2018

In 2014 biochemist Jennifer Doudna of the University of California at Berkeley awoke from a nightmare that would shift the focus of her world-class scientific career. Two years earlier, with her colleague Emmanuelle Charpentier, now director of the Max Planck Unit for the Science of Pathogens in Berlin, Doudna had achieved one of the most stunning breakthroughs in the history of biology, becoming the first to use a process called CRISPR-Cas9 to alter the genetic makeup of living organisms. Their “gene-editing” tool would allow scientists to efficiently insert or delete specific bits of DNA with unprecedented precision.

But as applications related to modifying human genes were soon reported in the scientific literature, Doudna began to worry. In the dream, a colleague asked if she would help teach someone how to use CRISPR (Clustered Regularly Interspaced Short Palindrome Repeats). She followed him into a room to be greeted by Adolph Hitler wearing a pig face. The nightmare reinforced her belief that public discussion of the technology was far behind the breakneck pace of its emerging applications. She feared a public backlash that would prevent beneficial forms of gene-editing research from moving forward.

Resource type: article: Web Page

Compatibility of breeding techniques in organic systems

Publication date: 01/01/2018

This IFOAM position paper states that “New genetic engineering technologies …are not compatible with organic farming and must not be used in organic breeding or organic production.” It goes on to list the specific techniques, and calls for “clear legal definitions to be in place which are regularly updated”.

The paper also states “Products obtained through genetic engineering processes should not be released into the environment. In any case such releases should not take place without a prior rigorous, multistakeholder designed and agreed risk assessment protocol that includes input from the organic sector and like-minded movements, and an assessment of the possibility to prevent the presence of such products in organic products and GMO-free products.”

IFOAM asks for the ‘Polluter Pays’ principle to be maintained. This means “On-going costs and harms to organic and non-GMO supply chains from contamination by these new techniques … should be borne by the developers and/or the company that puts the product on the market.” Although the principle is one of the EU directives, sadly it is not guaranteed in post-Brexit Britain.

Resource type: article: Web Page

For whom? Questioning the food and farming research agenda

Publication date: 01/01/2018

A special magazine exploring where the power lies in setting our food and farming research agenda.

The UK’s Food Ethics Council asked international experts to explore where the power lies in setting our food and farming research agenda. We also asked who benefits from both publicly and privately funded research. We believe the status quo research agenda is not delivering the public good required for a food system that serves the needs of people, planet and animals.

This special collection of articles starts addressing key questions about how the research agenda is set in food and farming, unmasking and challenging the dominant research paradigm, and highlighting inclusive alternatives to deliver public good. The report is aimed at research institutions, funding bodies, government officials, CSOs and anyone with an interest in redefining the research agenda for the public good, especially in post-Brexit UK.

The report includes contributions from: Miguel Altieri, Molly Anderson, Annelie Bernhart, Helen Browning, Ibrahima Coulibaly, Dan Crossley, Liza Draper, David Drew MP, Ralph Early, Liz Hosken, Toby Hodgkin, IPES-Food, Nic Lampkin, Tim Lang, Les Levidow, Steve McLean, Tom MacMillan, Renato Maluf, Ben Mepham, Dunja Mijatovic, Pat Mooney, Marion Nestle, Clara Nicholls, Helena Paul, Susanne Padel, Michel Pimbert, Jonathan Porritt, Claire Robinson, Suman Sahai, Ruth Segal, Steve Tones and Melanie Welham.

Resource type: Adobe Acrobat (.pdf)

The case against genetically modified crops

Publication date: 01/01/2018

The business case for GMOs is rarely explored in depth.

In a report subtitled “An environmental investor’s view of the threat to our global food system”, Trillium Asset Management,  a US-based employee owned investment manager with a focus on sustainability, looks at the environmental, social and regulatory risks as well as the reputational and financial risks of investing in genetically engineered crops.

Purveyors of transgenic products claim that GM farming boosts yields and farming incomes by saving on fossil fuels, pesticides, and labor. Another claim arising from this assumption is that GM farming represents a step toward environmental sustainability by decreasing emissions and the use of agricultural chemicals. GM advocates also maintain that GM crops pose no health risks to either the farmers or consumers.

None of these arguments have held up over extended periods of use or in the face of independent testing. Pesticide and herbicide-resistant crops (by far the most widely used GM varieties) actually lead to an increase in pesticide and herbicide use over time horizons of as little as four years.2 Financial gains, which farmers make through increased yields, are offset by increased spending on patented seeds, fertilizer, and herbicides or pesticides, leading to a net decrease in income for all but the largest mega-farms. These higher input costs are especially damaging when small, more marginal farmers experience crop failure. Elevated levels of bankruptcy and consolidation have frequently occurred following the deployment of GM crops.

Perhaps the most pervasive argument for GM crops is centered on the message that these crops are needed to “feed the world.” The underlying assumptions of this argument, however, are simply incorrect. At current levels of global production, there is enough food for every person on earth to have 3,000 calories per day. The problem lies with the varieties of crops being grown, lack of financial access and infrastructure, and food waste. One-quarter of all calories or, by weight, one-third of all food grown, goes uneaten. In the United States, this problem is compounded, with 60 million metric tons of food, equal to an estimated $162 billion in value, going uneaten every year. This equates to approximately 1500 calories of wasted food per person per day.

In fact, GM crops can actually exacerbate hunger issues by pressuring farmers in marginal areas to grow cash crops for export or extensive processing. Globally, approximately 80% of the GM crops grown are corn and soybeans, crops that are overwhelmingly used for animal feed and biofuels. The narrative that GM crops will lift poor farmers out of poverty by increasing crop yields is also specious. The more relevant barriers to economic growth and improved yields are lack of basic resources such as fertilizer, water, and transportation infrastructure.

We believe that for environmental, social, and governance (ESG)-focused investment strategies, agricultural biotech represents an unacceptable level of risk across a wide range of factors. The problem lies less with individual companies or products, but rather with how GM agriculture in its current iteration jeopardizes the whole agricultural system. Just as these risks are system-based, the consequences would manifest themselves by changing the very biological, economic, and social framework of food systems. Almost twenty years into the GM experiment, a range of these risks have become clear.

When taken together, we believe these risks form a very clear basis for exclusion of companies involved in agricultural biotechnology from an ESG investment strategy.

The original report was in 2014. Our link is to the updated version published in January 2018.

Resource type: Adobe Acrobat (.pdf)